Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVDP plus radiotherapy for newly diagnosed extranodal NK/T-cell lymphoma
ChiCTR-TNC-12002353Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of asparaginase escherichia coli, cisplatin, etoposide and dexamethasone in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) (2 cohorts), sponsored by West China Hospital of Sichuan University. Primary endpoints: overall response rate, time to progression and 2 more. Started Apr 2010; status: completed.
02
Drugs
asparaginase escherichia colicisplatinetoposidedexamethasone
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-TNC-12002353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-12002353.